Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PROF 
Profound Medical Corp (PROF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: PROF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 20.05% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 198.23M USD | Price to earnings Ratio - | 1Y Target Price 15.1 |
Price to earnings Ratio - | 1Y Target Price 15.1 | ||
Volume (30-day avg) 67784 | Beta 0.77 | 52 Weeks Range 5.63 - 11.42 | Updated Date 03/27/2025 |
52 Weeks Range 5.63 - 11.42 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.3225 | Actual -0.2 |
Profitability
Profit Margin -260.45% | Operating Margin (TTM) -236.41% |
Management Effectiveness
Return on Assets (TTM) -36.19% | Return on Equity (TTM) -60.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 147852849 | Price to Sales(TTM) 18.56 |
Enterprise Value 147852849 | Price to Sales(TTM) 18.56 | ||
Enterprise Value to Revenue 13.84 | Enterprise Value to EBITDA -5.75 | Shares Outstanding 30039800 | Shares Floating 27652245 |
Shares Outstanding 30039800 | Shares Floating 27652245 | ||
Percent Insiders 7.94 | Percent Institutions 50.52 |
Analyst Ratings
Rating 5 | Target Price 15.3 | Buy - | Strong Buy 5 |
Buy - | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Profound Medical Corp
Company Overview
History and Background
Profound Medical Corp. is a medical technology company focused on developing and commercializing customizable, incision-free therapies for prostate cancer and other diseases. It was founded in 2008 and went public in 2015. The company's focus has been on refining and expanding the applications of its TULSA-PRO system.
Core Business Areas
- TULSA-PRO: The primary focus is on the development, manufacturing, and commercialization of the TULSA-PRO system, which provides customizable, incision-free prostate ablation.
Leadership and Structure
The leadership team includes Arun Menawat (CEO), Aaron Davidson (CFO), and key personnel overseeing research and development, clinical affairs, and commercial operations. The organizational structure is typical of a medical device company, with departments focusing on engineering, regulatory affairs, sales, and marketing.
Top Products and Market Share
Key Offerings
- TULSA-PRO: TULSA-PRO is Profound Medical's core product, a transurethral ultrasound ablation system for prostate cancer. Market share is still developing, but the addressable market is significant with a large number of men diagnosed with prostate cancer annually. Competitors include conventional surgery, radiation therapy, and other focal therapies like HIFU and cryotherapy. Revenue data is dependent on adoption and sales cycles.
Market Dynamics
Industry Overview
The medical device industry is highly competitive and regulated, particularly in the area of cancer treatment. There's growing demand for minimally invasive procedures offering reduced side effects and improved patient outcomes.
Positioning
Profound Medical positions itself as offering a unique, customizable, and incision-free alternative to traditional prostate cancer treatments. Its competitive advantage lies in the precision and personalization offered by the TULSA-PRO system.
Total Addressable Market (TAM)
The estimated TAM for prostate cancer treatment is substantial, potentially reaching billions of dollars annually. Profound Medical is targeting a portion of this market by offering a niche solution appealing to patients seeking less invasive options. TAM varies but some analysis places it above $3 billion.
Upturn SWOT Analysis
Strengths
- Innovative technology (TULSA-PRO)
- Minimally invasive procedure
- Customizable treatment planning
- Potential for reduced side effects
Weaknesses
- Limited commercial history
- High initial capital expenditure for hospitals
- Dependent on regulatory approvals and reimbursement
- Relatively small company size
Opportunities
- Expanding indications for TULSA-PRO
- Growing awareness of minimally invasive options
- Partnerships with leading urology centers
- International market expansion
Threats
- Competition from established prostate cancer treatments
- Slow adoption rates by physicians
- Unfavorable reimbursement policies
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- BK Medical (Analogic)
- EDAP TMS SA (EDAP)
- SonaCare Medical
Competitive Landscape
Profound Medical's TULSA-PRO competes with traditional treatments, but also with HIFU systems and other focal therapy approaches. The competitive advantage is customizable ablation and real-time monitoring.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to TULSA-PRO adoption and sales. Early growth was slow initially, but the market is building to be a strong growth market.
Future Projections: Future growth projections depend on analyst estimates, regulatory approvals, and successful commercialization efforts.
Recent Initiatives: Recent strategic initiatives may include new clinical studies, partnerships, and market expansion efforts.
Summary
Profound Medical Corp is a specialized medical technology company with promising technology but faces challenges in market adoption and competition. Its innovative TULSA-PRO system offers a minimally invasive alternative for prostate cancer treatment, potentially leading to reduced side effects. The company's future success depends on expanding indications, establishing partnerships, and navigating regulatory and reimbursement hurdles. Profound Medical needs to carefully manage its financial resources and compete effectively against larger, established players in the urology market.
Similar Companies
- EDAP
- BK Medical (Analogic)
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and analyst opinions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Profound Medical Corp
Exchange NASDAQ | Headquaters Mississauga, ON, Canada | ||
IPO Launch date 2016-06-09 | Chairman of the Board & CEO Dr. Arun Swarup Menawat MBA, Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 142 | Website https://www.profoundmedical.com |
Full time employees 142 | Website https://www.profoundmedical.com | ||
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.